415 related articles for article (PubMed ID: 27799762)
21. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note.
Falsey AR; Becker KL; Swinburne AJ; Nylen ES; Snider RH; Formica MA; Hennessey PA; Criddle MM; Peterson DR; Walsh EE
Int J Chron Obstruct Pulmon Dis; 2012; 7():127-35. PubMed ID: 22399852
[TBL] [Abstract][Full Text] [Related]
22. Levels of soluble triggering receptor expressed on myeloid cells 1 in infectious exacerbations of chronic obstructive pulmonary disease.
Rohde G; Radsak MP; Borg I; Buhl R; Schultze-Werninghaus G; Taube C
Respiration; 2012; 83(2):133-9. PubMed ID: 21701149
[TBL] [Abstract][Full Text] [Related]
23. A three-step diagnosis of pediatric pneumonia at the emergency department using clinical predictors, C-reactive protein, and pneumococcal PCR.
Alcoba G; Keitel K; Maspoli V; Lacroix L; Manzano S; Gehri M; Tabin R; Gervaix A; Galetto-Lacour A
Eur J Pediatr; 2017 Jun; 176(6):815-824. PubMed ID: 28474099
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and Prognostic Value of Inflammatory Parameters Including Neopterin in the Setting of Pneumonia, COPD, and Acute Exacerbations.
Pizzini A; Lunger F; Sahanic A; Nemati N; Fuchs D; Weiss G; Kurz K; Bellmann-Weiler R
COPD; 2017 Jun; 14(3):298-303. PubMed ID: 28548632
[TBL] [Abstract][Full Text] [Related]
25. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia.
Duman D; Aksoy E; Agca MC; Kocak ND; Ozmen I; Akturk UA; Gungor S; Tepetam FM; Eroglu SA; Oztas S; Karakurt Z
Int J Chron Obstruct Pulmon Dis; 2015; 10():2469-78. PubMed ID: 26648709
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and inflammatory markers in pediatric pneumonia: a prospective study.
Berg AS; Inchley CS; Fjaerli HO; Leegaard TM; Lindbaek M; Nakstad B
Eur J Pediatr; 2017 May; 176(5):629-638. PubMed ID: 28281094
[TBL] [Abstract][Full Text] [Related]
27. Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia.
Hohenthal U; Hurme S; Helenius H; Heiro M; Meurman O; Nikoskelainen J; Kotilainen P
Clin Microbiol Infect; 2009 Nov; 15(11):1026-32. PubMed ID: 19548923
[TBL] [Abstract][Full Text] [Related]
28. Phenotyping COPD exacerbations using imaging and blood-based biomarkers.
Alotaibi NM; Chen V; Hollander Z; Hague CJ; Murphy DT; Leipsic JA; DeMarco ML; FitzGerald JM; McManus BM; Ng RT; Sin DD
Int J Chron Obstruct Pulmon Dis; 2018; 13():217-229. PubMed ID: 29386890
[TBL] [Abstract][Full Text] [Related]
29. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia.
Justo D; Lachmi S; Saar N; Joffe E; Atzmony L; Mashav N; Henis O; Sade B; Chundadze T; Steinvil A; Paran Y
Eur J Intern Med; 2009 Sep; 20(5):518-21. PubMed ID: 19712857
[TBL] [Abstract][Full Text] [Related]
30. The neutrophil/lymphocyte ratio is a better addition to C-reactive protein than CD64 index as a marker for infection in COPD.
Farah R; Ibrahim R; Nassar M; Najib D; Zivony Y; Eshel E
Panminerva Med; 2017 Sep; 59(3):203-209. PubMed ID: 28185443
[TBL] [Abstract][Full Text] [Related]
31. Prognostic role of D-dimer for in-hospital and 1-year mortality in exacerbations of COPD.
Hu G; Wu Y; Zhou Y; Wu Z; Wei L; Li Y; Peng G; Liang W; Ran P
Int J Chron Obstruct Pulmon Dis; 2016; 11():2729-2736. PubMed ID: 27843309
[TBL] [Abstract][Full Text] [Related]
32. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations.
Antonescu-Turcu AL; Tomic R
Curr Opin Pulm Med; 2009 Mar; 15(2):120-5. PubMed ID: 19532026
[TBL] [Abstract][Full Text] [Related]
33. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients.
Taylan M; Demir M; Kaya H; Selimoglu Sen H; Abakay O; Carkanat Aİ; Abakay A; Tanrikulu AC; Sezgi C
Clin Respir J; 2017 May; 11(3):311-317. PubMed ID: 26096858
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia.
Ortqvist A; Hedlund J; Wretlind B; Carlström A; Kalin M
Scand J Infect Dis; 1995; 27(5):457-62. PubMed ID: 8588135
[TBL] [Abstract][Full Text] [Related]
35. Prognostic utility of admission cell-free DNA levels in patients with chronic obstructive pulmonary disease exacerbations.
Avriel A; Rozenberg D; Raviv Y; Heimer D; Bar-Shai A; Gavish R; Sheynin J; Douvdevani A
Int J Chron Obstruct Pulmon Dis; 2016; 11():3153-3161. PubMed ID: 28003743
[TBL] [Abstract][Full Text] [Related]
36. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis.
Hedlund J; Hansson LO
Infection; 2000; 28(2):68-73. PubMed ID: 10782390
[TBL] [Abstract][Full Text] [Related]
37. Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination?
Korppi M
Pediatr Int; 2004 Oct; 46(5):545-50. PubMed ID: 15491381
[TBL] [Abstract][Full Text] [Related]
38. Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections.
Chen YH; Yao WZ; Gao JZ; Geng B; Wang PP; Tang CS
Respirology; 2009 Jul; 14(5):746-52. PubMed ID: 19659653
[TBL] [Abstract][Full Text] [Related]
39. COPD assessment test score and serum C-reactive protein levels in stable COPD patients.
Kang HK; Kim K; Lee H; Jeong BH; Koh WJ; Park HY
Int J Chron Obstruct Pulmon Dis; 2016; 11():3137-3143. PubMed ID: 27994452
[TBL] [Abstract][Full Text] [Related]
40. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD.
Clark TW; Medina MJ; Batham S; Curran MD; Parmar S; Nicholson KG
Eur Respir J; 2015 Jan; 45(1):76-86. PubMed ID: 25186260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
